Literature DB >> 10358138

Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP.

S G Tangye1, S Lazetic, E Woollatt, G R Sutherland, L L Lanier, J H Phillips.   

Abstract

The genetic defect in X-linked lymphoproliferative syndrome (XLP) is the Src homology 2 domain-containing protein SAP. SAP constitutively associates with the cell surface molecule, signaling lymphocytic activation molecule (SLAM), and competes with SH2-domain containing protein tyrosine phosphatase-2 (SHP-2) for recruitment to SLAM. SLAM exhibits homology with the mouse cell surface receptor 2B4. The human homologue of 2B4 has now been identified. It is recognized by the c1.7 mAb, a mAb capable of activating human NK cells. Human 2B4 became tyrosine phosphorylated following pervanadate-treatment of transfected cells and recruited SHP-2. SAP was also recruited to 2B4 in activated cells. Importantly, the 2B4-SAP interaction prevented the association between 2B4 and SHP-2. These results suggest that the phenotype of XLP may result from perturbed signaling not only through SLAM, but also other cell surface molecules that utilize SAP as a signaling adaptor protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10358138

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

Review 1.  Signaling activities of gammaherpesvirus membrane proteins.

Authors:  B Damania; J K Choi; J U Jung
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  mSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2.

Authors:  Z Yu; M Maoui; L Wu; D Banville; S Shen
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

Review 3.  Up on the tightrope: natural killer cell activation and inhibition.

Authors:  Lewis L Lanier
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

Review 4.  Inhibitory receptors on lymphocytes: insights from infections.

Authors:  Pamela M Odorizzi; E John Wherry
Journal:  J Immunol       Date:  2012-04-01       Impact factor: 5.422

5.  Absence of mouse 2B4 promotes NK cell-mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis.

Authors:  Stephen N Waggoner; Ruth T Taniguchi; Porunelloor A Mathew; Vinay Kumar; Raymond M Welsh
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

6.  A "three-pronged" binding mechanism for the SAP/SH2D1A SH2 domain: structural basis and relevance to the XLP syndrome.

Authors:  Peter M Hwang; Chengjun Li; Massimo Morra; Jennifer Lillywhite; D Ranjith Muhandiram; Frank Gertler; Cox Terhorst; Lewis E Kay; Tony Pawson; Julie D Forman-Kay; Shun-Cheng Li
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

7.  Properties of human blood monocytes. II. Monocytes from healthy adults are highly heterogeneous within and among individuals.

Authors:  Dorothy Hudig; Kenneth W Hunter; W John Diamond; Doug Redelman
Journal:  Cytometry B Clin Cytom       Date:  2013-12-10       Impact factor: 3.058

Review 8.  X-linked lymphoproliferative disease: genetic lesions and clinical consequences.

Authors:  Andrew J MacGinnitie; Raif Geha
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

9.  Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells.

Authors:  Antje K Kretzschmar; Michaela C Dinger; Christian Henze; Katja Brocke-Heidrich; Friedemann Horn
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

10.  X-linked lymphoproliferative disease in an adult.

Authors:  Takumi Hoshino; Hirokazu Kanegane; Noriko Doki; Hiroyuki Irisawa; Tohru Sakura; Yoshihisa Nojima; Shuichi Miyawaki; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.